21.47
0.00 (0.0%)
0.00 (0.0%)
Upgrade to Real-Time
Premarket
Best deals to access real time data! |
Ultimate Trader (Monthly)
Monthly Subscription
for only
|
Small Cap Basic
Monthly Subscription
for only
|
Big Cap Pro
Monthly Subscription
for only
|
VAT not included
|
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Celldex Therapeutics Inc | CLDX | NASDAQ | Common Stock |
Price Change | Change Percent | Stock Price | Last Traded ![]() |
|
---|---|---|---|---|
0.00 | 0.0% | 21.47 | 06:33:24 |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
21.47 |
Bid Price | Ask Price | Spread | News | |
---|---|---|---|---|
16.05 | 21.47 | 5.42 | - | - |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
- | 0 | $ 21.47 | USD |
Celldex Therapeutics Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
$ 849.50M | 39.57M | 39.55M | $ 3.57M | $ - | -3.58 | -8.20 |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | $ - | 0.00% | - | - |
Celldex Therapeutics News
Loading Messages....
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CLDX Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 20.74 | 21.845 | 19.71 | 21.01 | 305,145 | 0.73 | 3.52% |
1 Month | 23.25 | 26.85 | 15.37 | 21.95 | 1,019,289 | -1.78 | -7.66% |
3 Months | 18.06 | 30.17 | 15.37 | 23.08 | 747,395 | 3.41 | 18.88% |
6 Months | 17.10 | 30.17 | 14.56 | 20.83 | 667,406 | 4.37 | 25.56% |
1 Year | 1.86 | 30.17 | 1.77 | 12.40 | 1,199,887 | 19.61 | 1,054.3% |
3 Years | 1.05 | 30.17 | 0.17 | 4.53 | 1,270,875 | 20.42 | 1,944.76% |
5 Years | 4.59 | 30.17 | 0.17 | 3.99 | 1,480,642 | 16.88 | 367.76% |
Celldex Therapeutics Description
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. Its pipeline products are Varlilumab, CDX-301, CDX-1140, and CDX-3379. |